Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Dragani A et al. | The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. | 2010 | Blood | pmid:19887674 |
Kienzler JL et al. | Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. | 2010 | J Clin Pharmacol | pmid:19841157 |
Würtz M et al. | The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. | 2010 | Heart | pmid:19910291 |
Koeberle A et al. | The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. | 2010 | J. Pharmacol. Exp. Ther. | pmid:19934399 |
Armstrong PC et al. | Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. | 2010 | J. Thromb. Haemost. | pmid:19995405 |
Carroll RC et al. | Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. | 2010 | Thromb. Res. | pmid:19962724 |
Parmar JH et al. | Significant prostacyclin/thromboxane level imbalance after lower limb arterial angioplasty: a possible platelet function alteration. | 2010 | J Vasc Interv Radiol | pmid:20800778 |
Dharmasaroja PA and Sae-Lim S | Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers. | 2010 | Blood Coagul. Fibrinolysis | pmid:20689403 |
Milara J et al. | Cigarette smoke exposure up-regulates endothelin receptor B in human pulmonary artery endothelial cells: molecular and functional consequences. | 2010 | Br. J. Pharmacol. | pmid:20698855 |
Anauate MC et al. | Effect of isolated fractions of Harpagophytum procumbens D.C. (devil's claw) on COX-1, COX-2 activity and nitric oxide production on whole-blood assay. | 2010 | Phytother Res | pmid:20812280 |
Yassine HN et al. | Clinical determinants of aspirin resistance in diabetes. | 2010 | Diabetes Res. Clin. Pract. | pmid:20719400 |
Würtz M et al. | Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. | 2010 | JACC Cardiovasc Interv | pmid:20723855 |
Kim SY et al. | Platelet anti-aggregation activities of compounds from Cinnamomum cassia. | 2010 | J Med Food | pmid:20828311 |
Bao YM et al. | [Effect of precondition with GBE50 and Salviae miltionrrhizae on cycloxygenase-2 and its downstream effectors contents in ischemia/reperfusion myocardium]. | 2010 | Zhongguo Zhong Xi Yi Jie He Za Zhi | pmid:21066890 |
De la Cruz JP et al. | Differences in the in vitro antiplatelet effect of dexibuprofen, ibuprofen, and flurbiprofen in human blood. | 2010 | Anesth. Analg. | pmid:21048099 |
Renda G et al. | Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. | 2010 | Haematologica | pmid:21123440 |
Wang BZ et al. | [Association of Rs10487667 genetic polymorphism of thromboxane synthase with myocardial infarction in Uigur population of Xinjiang]. | 2010 | Zhonghua Yu Fang Yi Xue Za Zhi | pmid:21215134 |
Ge Y et al. | [Effect of ulinastatin on thromboxane Bâ‚‚ and deep vein thrombosis in elderly patients after hip joint replacement]. | 2010 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | pmid:21200097 |
Antonino MJ et al. | Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. | 2010 | Thromb. Res. | pmid:19446864 |
Santilli F et al. | Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. | 2010 | J. Thromb. Haemost. | pmid:20088941 |